The effect of cumin pearl on treatment of obesity

The effect of capsule contain cumin essential oil on weight and metabolic profiles of obese and overweight patients and its comparison with orlistat

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014043012438N8

Enrollment

Registered

2014-05-20

Start date

2014-04-27

Completion date

Unknown

Last updated

2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity and overweight. Obesity

Interventions

Intervention 1: Intervention group 1: Cumin essential oil capsule (Barij Essence pharmaceutical company, Kashan, Iran), orally, three times a day, for 8 weeks. Intervention 2: Intervention group 2: Or

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Overweight (Body mass index range: 25.2–48.8 kg/m 2) Aged 18–60

Exclusion criteria

Exclusion criteria: Those with malignancy Metabolic disorders Thyroid disorders Cardiovascular disorders Pregnancy and lactation Those using hormonal, antidiabetic, or anti-obesity medications

Design outcomes

Primary

Measure	Time frame
Weight change. Timepoint: Baseline and end of study. Method of measurement: Scale.	—

Secondary

Measure	Time frame
Total cholesterol. Timepoint: Baseline and end of study. Method of measurement: Enzymatic kit.;Insulin. Timepoint: Baseline and end of study. Method of measurement: ELISA kit.;Triglycerides. Timepoint: Baseline and end of study. Method of measurement: Enzymatic kit.;HDL-cholesterol. Timepoint: Baseline and end of study. Method of measurement: Enzymatic kit.;LDL-cholesterol. Timepoint: Baseline and end of study. Method of measurement: Enzymatic kit.;Glutathione. Timepoint: Baseline and end of study. Method of measurement: Spectrophotometry.;Fasting plasma glucose. Timepoint: Baseline and end of study. Method of measurement: Enzymatic kit.;Insulin resistance. Timepoint: Baseline and end of study. Method of measurement: Calculation using HOMA formula.;Thyroid hormones. Timepoint: Baseline and end of study. Method of measurement: ELISA kit.;Total antioxidant capacity. Timepoint: Baseline and end of study. Method of measurement: Spectrophotometry.	—

Measure

Time frame

Total cholesterol. Timepoint: Baseline and end of study. Method of measurement: Enzymatic kit.;Insulin. Timepoint: Baseline and end of study. Method of measurement: ELISA kit.;Triglycerides. Timepoint: Baseline and end of study. Method of measurement: Enzymatic kit.;HDL-cholesterol. Timepoint: Baseline and end of study. Method of measurement: Enzymatic kit.;LDL-cholesterol. Timepoint: Baseline and end of study. Method of measurement: Enzymatic kit.;Glutathione. Timepoint: Baseline and end of study. Method of measurement: Spectrophotometry.;Fasting plasma glucose. Timepoint: Baseline and end of study. Method of measurement: Enzymatic kit.;Insulin resistance. Timepoint: Baseline and end of study. Method of measurement: Calculation using HOMA formula.;Thyroid hormones. Timepoint: Baseline and end of study. Method of measurement: ELISA kit.;Total antioxidant capacity. Timepoint: Baseline and end of study. Method of measurement: Spectrophotometry.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Mohsen Taghizadeh

Kashan University of Medical Sciences

taghizadeh_m@kaums.ac.ir+98 36 1555 0021

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026